eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
25 hedge funds and large institutions have $5.48M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 9 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
14% less funds holding
Funds holding: 29 → 25 (-4)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
61% less capital invested
Capital invested by funds: $14M → $5.48M (-$8.49M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$91.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$77.3K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$66.5K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$53.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$33.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
-$4.03M |
| 2 |
CG
Column Group
San Francisco,
California
|
-$2.42M |
| 3 |
SOA
Sea Otter Advisors
Miami,
Florida
|
-$158K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26.5K |
| 5 |
EWA
EP Wealth Advisors
Torrance,
California
|
-$18.6K |
EFTR Hedge Fund Activity: Q4 2023 in Review
25 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q4 2023, worth a combined $5.48M — down 61% from $14M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of EFTR and 6 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $91.4K. The largest seller was SR One Capital Management, exiting entirely with an estimated $4.03M sold.
- 25 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q4 2023, down from 29 in Q3 2023.
- Funds reported $5.48M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q4 2023, down 61% quarter-over-quarter.
- 6 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q4 2023 and 9 closed out, a net change of -3 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q4 2023 was Vanguard Group, an estimated $91.4K added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q4 2023 was SR One Capital Management, an estimated $4.03M sold.
Based on aggregated 13F filings for Q4 2023.